Toxicological Analysis in Chemical Submission (TANCS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
IDF
-
Paris, IDF, France, 75004
- Hotel-Dieu Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Be of legal age (≥ 18) on the day of the exam,
- Have filed a complaint for a suspected chemical chemical,
- Be in possession of a judicial requisition requesting the to take biological samples (blood and urine)
- Claim to be the victim of a suspected chemical chemical submission that took place less than 5 days before the consultation,
- Be affiliated or entitled to a social security system,
- Having been informed of the research and not having opposed to his participation.
Exclusion Criteria:
- Patient under court protection
- Minor patient (< 18 ans),
- Patient under guardianship,
- Patient who does not speak French,
- Patient with psychotic / cognitive symptoms that may impair their judgment,
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Chemical Submission
Patients with a suspected chemical submission
|
Automated enzymatic assays Automated Immunoassay Urine Screening High Resolution Toxicological Screening
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Presence of one or more psychoactive substances
Time Frame: Day of inclusion
|
Identify the presence of one or more psychoactive substances in the tests performed (blood).
|
Day of inclusion
|
|
Presence of one or more psychoactive substances
Time Frame: Day of inclusion
|
Identify the presence of one or more psychoactive substances in the tests performed (urines).
|
Day of inclusion
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Questionnaire
Time Frame: Day of inclusion
|
Questionnaire to identify if voluntary intake of one or more psychoactive substance(s) within 24 hours leading to the suspicion of chemical submission.
|
Day of inclusion
|
|
Quantification of ethanol
Time Frame: Day of inclusion
|
Quantification of ethanol and/or ethylglucuronide (its metabolite) in samples
|
Day of inclusion
|
|
Quantification of ethylglucuronide
Time Frame: Day of inclusion
|
Quantification of ethanol and/or ethylglucuronide (its metabolite) in samples
|
Day of inclusion
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: DUFAYET Laurène, MD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- APHP200054
- 2019-A03134-53 (Other Identifier: ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.